NEW YORK (GenomeWeb) – GenomeDx today announced an agreement with Prime Health Services providing coverage of GenomeDx's prostate cancer test.
Under the terms of the deal, the test, called Decipher, will be covered by Prime Health for patients whose physicians order it. Prime Health's network includes 9 million covered lives and brings the total number of covered lives for Decipher to about 120 million, GenomeDx said.
Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors, San Diego-based GenomeDx said.